The accuracy of 99mTc-PSMA imaging in the re-staging and response monitoring in patients with metastatic prostate cancer
Not Applicable
- Conditions
- Metastatic prostate cancerCancer - Prostate
- Registration Number
- ACTRN12622001030763
- Lead Sponsor
- Fiona Stanley Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Male
- Target Recruitment
- 20
Inclusion Criteria
1.Male patients aged> 18 yrs
2.History of histologically confirmed prostate cancer
3.Metastatic patients who are considered for treatment with 177 Lu – PSMA
4.Ability to understand and the willingness to sign a written informed consent
Exclusion Criteria
1.Life expectancy less than 6 months;
2.Unable to give informed consent
3.Unable to comply with required scanning schedule.
4.Other malignant tumors that are likely to express PSMA, such as salivary gland, renal or hepatocellular carcinoma.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method